Register for email alerts and news feeds:
This journal | BMJ Group
rss
Gut 2002;50:749-750; doi:10.1136/gut.50.6.749
Copyright © 2002 BMJ Publishing Group Ltd & British Society of Gastroenterology.
Gut 2002;50:749-750
© 2002 by Gut

COMMENTARY

Liver disease

HCC: What's the score

D Shouval

The Liver Unit, Hadassah University Hospital, Jerusalem, Israel

Correspondence to:
Correspondence to:
D Shouval, The Liver Unit, Hadassah University Hospital, Jerusalem, Israel;
Shouval@cc.huji.ac.il


Choosing a scoring system for staging hepatocellular carcinoma is a difficult task

Primary hepatocellular carcinoma (HCC) is a common neoplasm in East Asia, Africa, and the Mediterranean countries, with an age adjusted incidence rate of up to 20–28 cases per 105 in men. Major progress has been made in the prevention of HCC through universal vaccination of neonates and children at risk worldwide, yet available treatment options for patients with established tumours rarely lead to complete cure. HCC is recognised for its heterogeneous clinical and biological presentation, variable natural course, and its relationship to defined risk factors and aetiologic agents, as well as the difficulty in predicting response to different modes of treatment. The time interval from an undetectable tumour to a 2 cm lesion may vary between four and 12 months which leaves a relatively narrow window for optimal intervention in already established tumours with a fast doubling time. In the past decade, a number of new palliative and . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto
I Levy and M Sherman
Gut 2002 50: 881-885. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Pool-Zobel, B. L., Selvaraju, V., Sauer, J., Kautenburger, T., Kiefer, J., Richter, K. K., Soom, M., Wolfl, S. (2005). Butyrate may enhance toxicological defence in primary, adenoma and tumor human colon cells by favourably modulating expression of glutathione S-transferases genes, an approach in nutrigenomics. Carcinogenesis 26: 1064-1076 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Cardiology Jobs

Gastroenterology Jobs